JP2024511977A - 抗ｉｌｔ３抗体によるがんの治療方法 - Google Patents

抗ｉｌｔ３抗体によるがんの治療方法 Download PDF

Info

Publication number
JP2024511977A
JP2024511977A JP2023556755A JP2023556755A JP2024511977A JP 2024511977 A JP2024511977 A JP 2024511977A JP 2023556755 A JP2023556755 A JP 2023556755A JP 2023556755 A JP2023556755 A JP 2023556755A JP 2024511977 A JP2024511977 A JP 2024511977A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511977A5 (https=
Inventor
ブランディッシュ，フィリップ・イー
チェン，メイ
ロボダ，アンドレイ
ネボジン，マイケル
ウ，カイ
ジャン，ダピン
ジャン－フーバー，ジエ
Original Assignee
メルク・シャープ・アンド・ドーム・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク・シャープ・アンド・ドーム・エルエルシー filed Critical メルク・シャープ・アンド・ドーム・エルエルシー
Publication of JP2024511977A publication Critical patent/JP2024511977A/ja
Publication of JP2024511977A5 publication Critical patent/JP2024511977A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023556755A 2021-03-19 2022-03-17 抗ｉｌｔ３抗体によるがんの治療方法 Pending JP2024511977A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163779P 2021-03-19 2021-03-19
US63/163,779 2021-03-19
PCT/US2022/020714 WO2022197900A1 (en) 2021-03-19 2022-03-17 Methods for treating cancer with anti-ilt3 antibodies

Publications (2)

Publication Number Publication Date
JP2024511977A true JP2024511977A (ja) 2024-03-18
JP2024511977A5 JP2024511977A5 (https=) 2025-03-24

Family

ID=83320983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556755A Pending JP2024511977A (ja) 2021-03-19 2022-03-17 抗ｉｌｔ３抗体によるがんの治療方法

Country Status (10)

Country Link
US (1) US20240317854A1 (https=)
EP (1) EP4308243A4 (https=)
JP (1) JP2024511977A (https=)
KR (1) KR20230158057A (https=)
CN (1) CN117412771A (https=)
AU (1) AU2022239502A1 (https=)
BR (1) BR112023018921A2 (https=)
CA (1) CA3212604A1 (https=)
MX (1) MX2023010825A (https=)
WO (1) WO2022197900A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712518B (zh) * 2017-11-17 2025-03-25 默沙东有限责任公司 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021503280A (ja) * 2017-11-17 2021-02-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198731B2 (en) * 2017-01-20 2021-12-14 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
CN112469730A (zh) * 2018-05-10 2021-03-09 加利福尼亚大学董事会 用于治疗癌症的ccl21和检查点抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021503280A (ja) * 2017-11-17 2021-02-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, vol. 28, Suppl.5, JPN6026008496, 2017, pages 72 - 234, ISSN: 0005813129 *
ANNALS OF ONCOLOGY, vol. 30, JPN6026008494, 2019, pages 405 - 411, ISSN: 0005813127 *
CLINICALTRIALS.GOV ARCHIVE NCT03918278 ON 2021_03_18, JPN6026008497, 18 March 2021 (2021-03-18), ISSN: 0005813130 *
J. CLIN. ONCOL., vol. 38, JPN6026008495, 2020, pages 1000, ISSN: 0005813128 *

Also Published As

Publication number Publication date
BR112023018921A2 (pt) 2023-12-05
KR20230158057A (ko) 2023-11-17
EP4308243A4 (en) 2025-02-26
AU2022239502A1 (en) 2023-10-05
CA3212604A1 (en) 2022-09-22
CN117412771A (zh) 2024-01-16
WO2022197900A1 (en) 2022-09-22
US20240317854A1 (en) 2024-09-26
AU2022239502A9 (en) 2024-02-22
MX2023010825A (es) 2023-12-08
EP4308243A1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US20200277398A1 (en) Humanized antibodies against ceacam1
JP2024038251A (ja) 抗ｐｄ－１抗体によるがんの処置方法
TW202137984A (zh) 用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
US20200317803A1 (en) Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
JP2023515675A (ja) Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法
CN115397861A (zh) 用于癌症的组合治疗
KR20210088640A (ko) 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법
KR20240038008A (ko) 암 치료 방법 및 조성물
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
US20240042020A1 (en) Anti-garp-tgf-beta1/pd-1 combination therapy
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
WO2023192478A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
HK40109234A (zh) 用於治疗癌症的方法和组合物
HK40118859A (zh) 用於治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗
AU2021330872A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310